Gilead Announces FDA Approvad Supplemental New Drug Application For Use Of Veklury In COVID-19 Patients With Severe Renal Impairment, Including Those On Dialysis
Portfolio Pulse from Benzinga Newsdesk
Gilead Sciences has announced that the FDA has approved a supplemental new drug application for the use of Veklury in COVID-19 patients with severe renal impairment, including those on dialysis.
July 14, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The FDA approval of Gilead's supplemental new drug application for Veklury could potentially increase the company's revenues as it expands the drug's target market to include COVID-19 patients with severe renal impairment.
The FDA approval of Gilead's supplemental new drug application for Veklury expands the drug's target market to include COVID-19 patients with severe renal impairment, including those on dialysis. This could potentially increase the company's revenues as it allows the company to sell the drug to a wider range of patients.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100